Bifogade filer
Annual General Meeting of Infant Bacterial Therapeutics
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Infant Bacterial Therapeutics via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2024-05-08 18:11:00
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2024, among other things, the following was resolved:
- to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet;
- that no dividend is made;
- discharge from liability granted to Board members and the managing director,
- that the Board shall consist of five members without deputies;
- that remuneration shall be paid to the Chairman of the Board of SEK 340,000 and an unchanged additional remuneration for the work as Chairman of the Board of SEK 400,000 and to other Board members not employed by the company of SEK 170,000 each;
- that remuneration shall be paid to the members of the Remuneration Committee of SEK 44,000 to the Chairman and SEK 22,000 to each of the other members of the Remuneration Committee;
- that remuneration shall be paid to the members of the newly established Audit Committee of SEK 50,000 to the Chairman and SEK 25,000 to the other members of the Audit Committee;
- that the audit fee be paid according to approved invoice;
- re-election of Margareta Hagman, Eva Idén, Anthon Jahreskog, Kristina Sjöblom Nygren and Peter Rothschild as Board members;
- re-election of Peter Rothschild as Chairman of the Board;
- re-election of the registered accounting firm Deloitte AB;
- on appointment of the Nominating Committee in accordance with the Nominating Committee’s proposal;
- approval of the Board’s remuneration report;
- authorization for a new issuance of shares in accordance with the Board’s proposal; and
- implementation of an incentive program for the company’s employees and key persons engaged as consultants through the issuance of a maximum of 165,000 warrants in accordance with the Board’s proposal. The warrants shall entitle to subscription for a maximum of 165,000 B-shares in the company during the period June 1, 2027 up to and including September 30, 2027 at a subscription price corresponding to 200 percent of the volume-weighted average price of the company’s share according to Nasdaq Stockholm’s official price list during ten trading days before May 8, 2024.